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16mg/kg/day. The target area under the curve (AUC) was deﬁned
as 17.500 g*h/l and was assessed on day 1 and day 4 based on 3
blood samples. Dose adjustment was performed before the second
dose. Primary endpoint was A&E, secondary endpoints were veno-
occlusive disease (VOD), graft versus host disease (GvHD). A risk
factor analyses was performed using logistic regression.
Results: Between 6/2003 and 6/2006 60 pts were included (30
IVdtBU and 30 POBU). The IVdtBU and POBU groups were
comparable regarding age, sexe, indication for SCT, match-grade
and donor-source. The A&E rates for the IVdtBU and POBU
were 83.3% and 40%, respectively (OR 7.3; 95% CI 2,1-26;
p0.002). VOD occurred in 33% and 13% of patients, respectively
(P0,1). No difference in GvHD (grade2) was found. Average
AUC after the ﬁrst dose was 20.710 g*h/l and decreased after
targeting to 18.920 g*h/l. However, interpatient variation re-
mained comparable. The pharmacokinetic data showed a large
difference between the clearances of busulfan in children as com-
pared to adults. Clearance correlated well to body surface area and
seemed to be constant at all ages, whereas clearance divided to
bodyweight decreased as a function of age.
Conclusions: IVdtBU resulted in higher A&E rates compared to
POBU. A non-signiﬁcantly trend to more VOD in the IVdtBU
group was observed. Because of the generally high AUC of day 1
starting dose might be lowered. Once daily dosing of IV busulfan
with TDM was feasible in routine clinical practice and improved
the A&E rates for SCT in children.
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OUTCOMES OF CORD BLOOD TRANSPLANTATION FOR HURLER’S SYN-
DROME. AN EUROCORD-WORKING PARTY INBORN ERRORS EBMT
SURVEY
Boelens, J.J.1, Bierings, M.1, Wynn, R.2, O’Meara, A.3, Veys, P.4,
Bertrand, Y.5, Wraith, E.2, Cavazzana-Calvo, M.6, Wulffraat, N.1,
Gluckman, E.7, Rocha, V.7 1UMCU/WKZ: Dept. Heamatology/Immu-
nology/BMT, Utrecht, Netherlands; 2Royal Manchester Children’s Hos-
pital, Manchester, United Kingdom; 3Our Lady’s Hospital for Sick
Children, Dublin, Ireland; 4Great Ormond Street Hospital, London,
United Kingdom; 5Debrousse Hospital, Lyon, France; 6Hopital Necker-
Enfants Malades, Paris, France; 7Saint Louis Hospital/EUROCORD,
Paris, France.
Background: Hurler’s syndrome (HS), the most severe form of
mucopolysaccharidosis type-I causes progressive deterioration of
the central nervous system and death in childhood. Allogeneic-
stem cell transplantation (SCT) before the age of two years halts
disease progression and prolongs life. Graft-failure and mixed
chimerism limits the success of SCT for HS. (Unrelated) cord
blood grafts are suggested to be a good alternative source for bone
marrow.
Methods: Patient registered to EUROCORD-database and
EBMT-Hurler syndrome database were included. Between 1991
and 2004 forty-two patients received an (unrelated)-cord blood
transplant. The children were evaluated for engraftment, adverse
event and effects on disease symptoms. A risk factor analyses was
performed using logistic regression.
Results: From 40 patients enough data was available. After a
median follow up period of 14 (7-84) mths the “alive and en-
grafted” rate was 69% after ﬁrst SCT. Donors used were: 4 HLA-
identical family and 36 unrelated cord blood (23 mismatched: 18
5/6-matched and ﬁve 4/6-matched). With the exception of 2, all
patients received a myeloablative conditioning regimen. Cell dose
used was median 7.9 (1.5-32) *107 NC/kg and 2,6 (0,7-25) *105
CD34/Kg. In multivariate logistic regression analyses, year of
transplantation (2000 vs. 2001: A&E 40 vs 84%: OR 7,5 range
1,7-30, p0.007) and NC-dose of less than 5*107 NC/kg (OR 6,4,
range 1,7-39: p 0.045) were found to be risk factors for graft-
failure. Only 2 of the 27 patients A&E patients showed a mixed
chimerism (86 and 92%: still increasing). All patients had normal
enzyme levels. Acute-GvHD (grade1) was observed in 15%,
while chronic-GvHD was seen in 19% (extensive 8%) of patients
at risk. SCT improved somatic features of HS.
Conclusion: Outcome following cord blood SCT for Hurler’s
syndrome is encouraging. (U)CB is a good alternative stem cell
source and might even be preferential since cord-blood appeared
to increase the likelihood of sustained engraftment resulting in
full-donor chimerism and normal enzyme levels.
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CLINICAL OUTCOME OF HUMAN HERPES-6 REACTIVATION AFTER
HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN
Pagter, A. de1, Sanders, L.1, Rossen, J.2, Schuurman, R.2, Wolfs, T.1,
Versluys, B.1, Boelens, J.J.1 1UMCU/WKZ: Dept. of Haematology/
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Background: Although human herpes virus 6 (HHV6) is known
to reactivate during haematopoietic cell transplantation (HCT)
and is suggested to be associated with severe clinical manifestations
in adults, the clinical signiﬁcance in children remains controversial.
In this study we investigated the incidence of HHV6 reactivation
and HCT-associated morbidity and mortality in children.
Methods: Between 1/2004 and 4/2006 59 patients, median age
6.6y (0.1-18.1), underwent 68 allogeneic HCTs. By quantitative
PCR HHV6, EBV, CMV and adenovirus (AdV)-plasma loads were
measured once a week. Clinical features, engraftment, number of
transfusions, HCT-associated mortality and morbidity (like
GvHD) were monitored. Antiviral treatment for HHV-6 reactiva-
tion was only given from 4/2005 for those with clinical symptoms
assumed to be associated with HHV6. HHV6 reactivations were
grouped in group I (no HHV6), group II (loads 1000cp/mL) and
group III (loads1000cp/mL). CMV, EBV and AdV-reactivations
were treated according to local guidelines. A risk factor analyses
was performed using logistic regression.
Results: 36 HLA-id and 23 HLA non-id grafts were used: 44
bone marrow/PBSCs and 15 cord blood grafts. Median follow up
was 17 (5-35)mths. HHV6 reactivation occurred in 40/59 (67%)
with 33/40 (82%) occurring within the ﬁrst 30 d post-HCT. 23/59
(39%) had HHV6 loads above 1000cp/mL (group III). Groups did
not differ regarding sex, age, donor source or HLA-disparity. In
multivariate analysis HHV6 reactivation was associated with a
lower survival in group III (OR 0,16; range 0,03-0,89; p0.035) as
well as with more multiple viral reactivations (p0,049: OR 5,5;
range 1,1-29) were seen in this group. In 11/13 multiple viral
reactivation HHV6 was the ﬁrst viral reactivation. There was a
non-signiﬁcant trend for more grade 2-4 acute-GvHD (p0,058
OR 4,3; range 0,8-18) in group III. HHV6 didnot inﬂuence period
of neutro-trombocytopenia.
Conclusion: HHV6 reactivation is common after HCT in chil-
dren and is associated with a higher rate of multiple viral reacti-
vations, aGvHD and with a lower survival rate. Although the exact
role of HHV6 reactivation in transplantation associated morbidity
and mortality has to be elucidated, early detection and initiation of
therapy might inﬂuence the outcome.
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JOB SATISFACTION AMONG ADVANCED PRACTICE NURSES WITHIN
THE PEDIATRIC BLOOD AND MARROW TRANSPLANT CONSORTIUM
Browning, B.1, Thormann, K.1, Coyne, K.1, Halverson, T.1, The Pedi-
atric Blood and Marrow Transplant Consortium Nursing Discipline.2
1Children’s Memorial Hospital, Chicago, IL; 2Pediatric Blood and Mar-
row Transplant Consortium.
Introduction:
Advanced Practice Stem Cell Transplant (SCT) Nursing pro-
vides unique challenges associated with the medical science of
SCT, current healthcare environment and intense relationships
with patients and families due to the demanding nature of this
therapy. Although job satisfaction among nurses has been discussed
in the literature, the focus has been on work related and psycho-
logical stresses of SCT staff nurses working in inpatient SCT units
1,2. To date little if any research has been done exploring job
satisfaction speciﬁc to Advanced Practice SCT Nurses (APSCTN)
who have become integral members of the pediatric SCT team.
Methods:
Pediatric Blood and Marrow Transplant Consortium (PBMTC)
Nursing Discipline members completed a simple questionnaire
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exploring job satisfaction and factors contributing to job satisfac-
tion speciﬁc to pediatric SCT.
Results:
Of the participants, 90% of the respondents categorized them-
selves as APSCTN, some with additional responsibilities including
research and education and 85% are employed full time. 75% of
the respondents provide direct patient care with additional duties
in other areas.
Employing a Lickert-type scale from 1-10, 1 being very unsatis-
ﬁed/very burnt out, 10 being very satisﬁed/not burnt out, 50% of
APSCTN categorized themselves as a 7 or greater with overall job
satisfaction. When characterizing current job burn out, 60% re-
sponded between 1-6, however when describing burnout about
nursing as a profession, 80% responded as a 7 or greater (Table 1).
Job satisfaction was associated with direct patient/family interac-
tion, clinical care, and satisfying relationships with MD’s and
medical staff. Conﬂict with hospital administration, understafﬁng
and difﬁculties with other hospital departments are cited as having
negative impact on job satisfaction.
Conclusions:
Job satisfaction remains high in the SCT discipline despite dif-
ﬁcult interactions with hospital departments, administration and
chronic understafﬁng. However, nursing burnout remains a signif-
icant concern in pediatric SCT and should be addressed in this
unique group of professionals.
References:
1. Stutzer, C. Work Related Stresses of Pediatric Bone Marrow
Transplant Nurses. Journal of Pediatric Oncology Nursing. 1989;
6:70-78
2. Molassiostis, A and OBA van den Akker. Psychological Stress
in Nursing and Medical Staff on Bone Marrow Transplant Units.
Bone Marrow Transplantation. 1995; 15: 449-454.
Scale 1-10; 1 Very Unsatisﬁed/Very Burnt Out, 10 Very Satisﬁed/
Not Burnt out (n20)
<3 4-6 7-9 10
Job Satisfaction 2/20 8/20 10/20 0/20
Burnout in Current Job 4/20 8/20 6/20 2/20
Burnout Nursing as a Profession 1/20 3/20 9/20 7/20
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FASCIITIS AS A MANIFESTATION OF CHRONIC GRAFT VERSUS HOST
DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN CHILDREN AND ADOLESCENTS: A SINGLE IN-
STITUTION EXPERIENCE
Duncan, C.N.1,2, Myers, K.L.1,2, Lehmann, L.E.1,2 1Dana Farber
Cancer Institute, Boston, MA; 2Children’s Hospital Boston, Boston, MA.
Chronic graft versus host disease (CGVHD) remains one of
the most challenging obstacles to successful outcome following
allogeneic hematopoietic stem cell transplantation (HSCT). Al-
though the incidence of CGVHD is less in children than in
adults the impact is devastating as both disease and therapy can
profoundly impact growth, development and functional out-
come. Fasciitis is a rare manifestation of CGVHD that can
occur without other organ involvement. Histologically edema
and ﬁbrosis are present in the septae separating subcutaneous fat
lobules and in the muscular fascia beneath; overlying epidermis
is unaffected. Patients present with painful edema that almost
always progresses to fascial scarring. Ultimately the process
leads to loss of tissue ﬂexibility and a dimpled “peu d’orange “
appearance of the skin associated with poor functional and
cosmetic outcome. From January 1999 through December 2005
we performed 305 allogeneic HSCT; 5 patients received donor
lymphocyte infusions (DLI) during this time.40 had signiﬁcant
CGVHD, 9 post- related SCT, 31 post-unrelated donor SCT
and one following DLI. Of these patients 8 have been diagnosed
with signiﬁcant fasciitic CGVHD, 1 after a 3rd DLI, 3 after
related donor SCT (2nd SCT for one)and 4 following matched
unrelated donor(UD) SCT. 2 patients received peripheral blood
stem cells as the donor source; the remaining 5 received bone
marrow.3 had acute or chronic leukemias and 1 had an immu-
nodeﬁciency. The children ranged from 4-17 years of age at the
time of diagnosis and the diagnosis occurred 7 mos to 2 yrs after
HSCT/DLI. All patients had oral GVHD at diagnosis; 7/8 had
no other CGVHD. Excluding the patient developing fasciitis
post-DLI, all failed to respond to steroid therapy including
doses of up to 3mg/kg/day. Currently one child has died of
infection with aspergillus and atypical mycobacterium, 2 are off
all immunosuppression with resolution of disease after therapy
with MMF and steroids, 2 have disease control on weaning
immunosuppression including MMF and 3 have active disease
that impacts mobility despite multiagent therapy. No patient
with leukemia has had disease recurrence. Fasciitis can occur
with minimal other manifestations of CGVHD and inital ﬁnd-
ings such as painful edema or fascial thickening may be subtle.
Steroid therapy may prove ineffective illuminating the necessity
for other therapeutic agents as signiﬁcant functional limitations
occur if the disease can not be controlled.
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SEVERE VENO-OCCLUSIVE DISEASE AFTER BONE MARROW TRANS-
PLANTATION IN PREMATURE MONOZYGOTIC TWINS WITH FAMILIAL
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (FLH)
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1University Hospital Muenster, Department of Pediatric Hematology
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Introduction: Familial hemophagocytic lymphohistiocytosis
is a rare histiocytic disorder with hepatosplenomegaly, fever,
infections and hemophagocytosis visible in biopsies of hemato-
poietic and lymphoid tissue. Hematopoietic stem cell transplan-
tation is the only curative option. Bone marrow transplant
recipients with FLH are at an increased risk for VOD as busul-
fan-based conditioning regimens add to liver toxicity. Here, we
report two female, premature, identical twins with FLH and
severe VOD following allogeneic BMT. Case reports. After
diagnosis of FLH in the 2 months-old twins in spring 2006, the
children achieved complete remission using protocol HLH-
2004 (dexamethasone, etoposide, CsA) after 3 months. The girls
received an unrelated matched marrow transplant from the same
donor. The preparative regimen consisted of i.v. busulfan
16mg/kg BW, cyclophosphamide 200mg/kg BW and ATG
40mg/kg BW; GvHD prophylaxis was CsA and short course
MTX. Twin A was transplanted two weeks prior to her sister.
On day 9, she developed VOD associated with oliguria, renal
and respiratory insufﬁciency necessitating mechanical ventila-
tion. Further complications were disseminated intravascular co-
agulation (DIC) and potentially CsA-induced thrombocytope-
nic purpura requiring support with cellular and plasmatic blood
products. Deﬁbrotide and heparin were started with the onset of
VOD and DIC. On day 49, her bilirubin varies between 20
and 30mg/dl, but otherwise she displays improved hepatic pa-
rameters, is breathing spontaneously with minimal, additional
oxygen supply, has a sufﬁcient urine output and no infections or
GvHD under steroids and MMF. In twin B, the prophylactic use
of deﬁbrotide could not prevent VOD being diagnosed on day
13. However, she was not as severely affected as her sister
without the need for mechanical ventilation. In other respects,
she experienced the same complications. On day 35, her bil-
irubin varies between 15 and 25mg/dl, but she demonstrates a
gradual improvement of hepatic function, her respiratory sys-
tem is not impaired, the renal function slightly reduced under
CsA. Both girls engrafted rapidly and exhibit full donor cell
chimerism. Discussion. Signiﬁcant liver involvement in FLH
patients poses a considerable risk for developing VOD. The use
of deﬁbrotide could not prevent, but may have mitigated the
severity of VOD in the second child. Children with FLH and a
high risk for VOD may be considered for reduced intensity
conditioning regimens.
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